Clinical efficacy studies are not always required for biosimilars, and it's possible to resist if the FDA does ask for them. Sarfaraz K. Niazi, PhD, suggests a game plan.
My analysis of all biosimilars licensed by the FDA and EMA shows a common trend: Except in a few instances, all products were tested for clinical efficacy and safety; none of the tests failed, and where results were borderline, the FDA allowed adjustment of acceptance criteria to make approval possible. No product was tested in more than 1 indication, despite the allowance of all indications by the FDA and European Medicines Agency (EMA).
If you are one of the big pharma companies dabbling in biosimilars, you would prefer to conduct these studies because you are used to meeting with prescribers with published clinical studies in hand. Other companies, not as well grounded in the value of clinical studies, performed them because they kept thinking of biosimilars as new biologics and had great uncertainty in their abilities. This article is not for those who are fixed in their belief that clinical efficacy testing is needed. Here are a few points of advice for biosimilar developers. First, I continue to assert that big pharma will soon walk out of the biosimilars field; after my first prediction, I got a lot of wrath from big pharma, although several pulled out within a few months.
The Generics Experience Is Prologue
One should learn from history: The same things occurred when generic laws came into effect. First, big pharma predicted that use of generics would lead to the demise of millions of patients because only big pharma knows how to make safe products. That campaign was not successful, so they joined the party and began offering generic versions of their products (some still do). But when the bottom fell out with 70% to 90% price reductions, most big pharma companies went back to doing what they best, creating new products. The same will happen to biosimilars, once the price bottom falls.
It may be a surprise to some that clinical efficacy testing for biosimilars is not always a requirement for approval. When I reviewed all licensed products, I inquired why the FDA required these studies; to my surprise, the answer was that the developers offered these studies as part of establishing biosimilarity. If you provide the FDA or EMA with an extensive plan to test clinical efficacy and safety, the agency cannot say no. What if they discouraged these studies and there were safety issues?
The most glaring example of redundant efficacy testing was the approval of Retacrit (epoetin alfa) by Hospira, which conducted efficacy testing in 1000 individuals for its European submission. When Hospira applied for FDA approval using the same EU data, the application was rejected and the FDA required a stepwise approach which involves analytical characterization of the proposed biosimilar, then animal studies, possibly, and then comparative clinical studies. Instead of examining the extensive clinical efficacy proof, the FDA did not require any efficacy testing and accepted the EU study only as an ancillary study. The FDA and EMA are also not requiring clinical efficacy testing for products such as teriparatide, insulins, low-molecular-weight heparins, filgrastim, pegfilgrastim, and other cytokines with pharmacodynamic markers. Some products would not even need safety assessments, such as teriparatide, low-molecular-weight heparin, and insulins.
Here is how biosimilar developers should challenge the FDA if asked to do clinical efficacy testing:
In my recent interactions with both the FDA and EMA, there is an openness to receive creative approaches to establishing biosimilarity. We have more than 15 years of experience in seeing the approval of over 100 biosimilar products.
The reason I am insistent on helping biosimilar developers simplify the qualification process is that, so far, the approval of biosimilars has been disappointing; first, markets for biologic drugs are still very much controlled by big pharma; and second, this is keeping smaller companies from entering the field. The reason I am so confident is that I know exactly what it costs to manufacture biological products. Biosimilar antibodies should not cost more than $150/g to manufacture in Western countries. But, not surprisingly, the cost to patients is still about 100-fold; this must come down if the promise of biosimilars will be realized.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.